01—Abstract
Summary
Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported third-quarter 2025 results for the quarter ended September 27, 2025, in a press release furnished under Item 2.02 as Exhibit 99.1.
Revenue was $1.00 billiona, a decrease of 0.5% from $1.01 billion a year earlier. Excluding a 1.3% favorable foreign currency impact and a 0.2% reduction from a divestiture, organic revenue declined 1.6%. GAAP earnings per diluted share were $1.10, compared with $1.33 in the prior-year quarter, primarily due to a $0.33 per share loss from venture capital and other strategic investments.
Non-GAAP diluted EPS was $2.43b, down 6.2% from $2.59. GAAP operating margin rose to 13.3% from 11.6%, driven by lower restructuring costs, while non-GAAP operating margin eased to 19.7% from 19.9%. By segment, Research Models and Services (RMS) grew revenue 7.9% to $213.5 million, with organic growth of 6.5% driven mainly by large research model products.
Discovery and Safety Assessment (DSA) revenue fell 2.3% to $600.7 millionc, with organic decline of 3.1% on lower discovery and regulated safety assessment volume. Manufacturing Solutions revenue fell 3.1% to $190.7 million, with organic decline of 5.1% led by CDMO and Biologics Testing, partly offset by Microbial Solutions. For 2025, the company narrowed its revenue and non-GAAP EPS guidance to the middle and upper ends of prior ranges, respectively.
Reported revenue growth is now guided at (1.5)% to (0.5)%, and non-GAAP EPS at $10.10 to $10.30d, versus the prior $9.90 to $10.30. GAAP EPS guidance is $4.15 to $4.35, down from $4.25 to $4.65 previously. Management stated that demand remains stable and some signals suggest the industry may be recovering, but sustained improvement will take time and the company remains cautious.
02—Key points
Key Highlights
- Q3 2025 revenue of $1.00 billion, down 0.5% from $1.01 billion; organic revenue declined 1.6%
- GAAP diluted EPS of $1.10 vs. $1.33 a year earlier, reflecting a $0.33 per share loss from venture capital and strategic investments; non-GAAP diluted EPS of $2.43 vs. $2.59 (down 6.2%)
- GAAP operating margin improved to 13.3% from 11.6%, primarily from lower restructuring costs; non-GAAP operating margin was 19.7% vs. 19.9%
- RMS revenue rose 7.9% to $213.5 million (organic growth of 6.5%), while DSA fell 2.3% to $600.7 million and Manufacturing fell 3.1% to $190.7 million
- 2025 non-GAAP EPS guidance narrowed to $10.10 to $10.30 (from $9.90 to $10.30); GAAP EPS guidance lowered to $4.15 to $4.35 (from $4.25 to $4.65)
- 2025 reported revenue growth guidance of (1.5)% to (0.5)%, with organic growth guided at (2.5)% to (1.5)%
- Non-GAAP adjustments include third-party legal costs tied to U.S. government investigations into the NHP supply chain and advisory costs related to a Cooperation Agreement with a shareholder
03—Questions
Frequently Asked Questions
Why did GAAP EPS fall so much more than non-GAAP EPS in the third quarter?
The decline in GAAP EPS was primarily driven by a loss of $0.33 per share from certain venture capital and other strategic investments, compared with a $0.03 per share gain in the prior-year quarter. Non-GAAP results exclude these investment gains and losses, so non-GAAP diluted EPS declined only to $2.43 from $2.59.
What drove the difference between segment performance?
RMS grew revenue 7.9%, with organic growth of 6.5% due mainly to higher revenue for large research model products. DSA declined 2.3% (organic decline of 3.1%) on lower discovery and regulated safety assessment sales volume, and Manufacturing Solutions declined 3.1% (organic decline of 5.1%) on lower CDMO and Biologics Testing revenue, partly offset by Microbial Solutions.
What changed in the 2025 guidance?
The company narrowed its reported revenue growth and non-GAAP EPS ranges to the middle and upper ends of prior ranges, respectively. Non-GAAP EPS guidance is now $10.10 to $10.30. GAAP EPS guidance was lowered to $4.15 to $4.35 from $4.25 to $4.65, and the venture capital and strategic investment losses estimate was raised to $0.50 per share from about $0.17.
How is management describing the market outlook?
CEO James C. Foster said demand for the company's early-stage research and manufacturing products and services remains stable, and that positive signals suggest the industry may be on a path toward recovery. He added that sustained improvement will take time, that uncertainty remains in the healthcare sector, and that the company is remaining cautious.
04—Continue